Humacyte, Inc.
Financials
Valuation Metrics
Humacyte, Inc.'s Market Cap is $111M. At end of 2025 it was $152M. Ranked #3050 of 3,118 in US market (top 98%), #1414 of 1,474 on NASDAQ (top 96%), #256 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 97%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $111M | US#3,050/3,118 Sec#256/265 |
| Revenue | $2M | US#2,835/3,118 Sec#184/265 |
| Net Income | $-97M | US—/3,118 Sec—/265 |
| Total Assets | $138M | US#3,026/3,118 Sec#254/265 |
| Net Assets | $31M | US#2,870/3,118 Sec#229/265 |
| Employees | 184 | US#2,495/3,118 Sec#131/265 |
| Value | ||
| P/B | 3.54x | US#1,977/3,118 Sec#116/265 |
| P/S | 52.14x | US#2,921/3,118 Sec#168/265 |
| FCF Yield | -88.22% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROA | -70.05% | US#3,026/3,118 Sec#240/265 |
| Op. Margin | -5240.78% | US#2,832/3,118 Sec#178/265 |
| Revenue Growth | -73.64% | US#2,712/3,118 Sec#171/265 |
| Financial Health | ||
| Debt Ratio | 341.72% | US#2,184/3,118 Sec#214/265 |
| Total Debt | $66M | US#2,540/3,118 Sec#142/265 |
| FCF | $-98M | US#2,626/3,118 Sec#142/265 |
| Cash | $80M | US#2,344/3,118 Sec#190/265 |
| Current Ratio | 6.21x | US#379/3,118 Sec#120/265 |
| Performance | ||
| 1Y Return | -76.16% | US#3,051/3,118 Sec#255/265 |
| 1M Return | -23.66% | US#2,805/3,118 Sec#227/265 |
| From 52W High | -74.48% | US#3,016/3,118 Sec#245/265 |
| 1Y MDD | -76.23% | US#3,018/3,118 Sec#242/265 |
| Trading | ||
| Volume | 5,172,112 shares | US#400/3,118 Sec#27/265 |
| Trading Value | $2M | US#2,868/3,118 Sec#235/265 |
| Per Share | ||
| EPS | $-0.35 | US—/3,118 Sec—/265 |
| BPS | $0.11 | US#2,786/3,118 Sec#230/265 |
Company Info
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.